

Review

Epigenetic Regulation in Chondrogenesis

Takayuki Furumatsu* and Toshifumi Ozaki

*Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan*

Epigenetics is an essential mechanism to control gene expression and fundamental cellular processes. DNA methylation in CpG-rich promoters correlates with gene silencing. Histone modification including histone acetylation and deacetylation determines the stability of the chromatin structure. Condensed chromatin (heterochromatin), which has a higher-order histone-DNA structure, prevents the access of transcriptional activators to their target genes. The fundamental unit of eukaryotic chromatin consists of 146 bp of DNA wrapped around a histone octamer. Posttranslational modifications of the histone tail and the chromatin remodeling complex disrupt histone-DNA contacts and induce nucleosome mobilization. Histone acetylation of specific lysine residues in the histone tail plays a crucial role in epigenetic regulation. Histone acetylation is a dynamic process regulated by the antagonistic actions of 2 families of enzymes - the histone acetyltransferases (HATs) and the histone deacetylases (HDACs). The balance between histone acetylation and deacetylation serves as a key epigenetic mechanism for transcription factor-dependent gene expression and the developmental process. We review emerging evidence that DNA methylation, histone acetylation modified by HAT and/or HDAC, and transcription factor-associated molecules contribute to a mechanism that can alter chromatin structure, gene expression, and cellular differentiation during chondrogenesis.

Key words: epigenetics, DNA methylation, histone acetylation and HAT, histone deacetylation and HDAC, chondrogenesis

Functional musculoskeletal systems depend on the coordinated development of cartilage, bone, tendon, ligament, and muscle [1]. Genetic (DNA) codes play a key role in normal development and appropriate gene expression, called "genetic regulation", this sequential expression is interrupted or altered by genetic disorders. Although tissue-derived mesenchymal stem cells (MSCs) contain the same genetic information, each cell has a different gene expression and specific cellular function. The sequen-

tial differentiation of mesenchymal progenitors is tightly controlled by many transcriptional parameters. Tissue-specific transcription factors regulate the spatiotemporal gene expressions by associating with cis-acting elements such as promoters, enhancers, and silencers in the DNA sequences [2]. Transcriptional coactivators and corepressors also have important roles in transcriptional regulation. Since the decade of the genome project, "epigenetic regulation" (such as DNA methylation, histone modification, and chromatin remodeling) has been highlighted. Epigenetics ("epi" means "above") is defined as gene-regulating activity that does not involve changes in the underlying DNA code. The fundamental unit of eukaryotic chromatin,

Received February 16, 2010; accepted March 26, 2010.

*Corresponding author. Phone: +81-86-235-7273; Fax: +81-86-223-9727
E-mail: matino@md.okayama-u.ac.jp (T. Furumatsu)

the nucleosome, consists of 146 bp of genomic DNA wrapped around a histone octamer (2 sets each of H2A, H2B, H3, and H4 core histones) [3]. DNA methylation is not only essential for mammalian development but also is a major epigenetic mechanism [2, 4, 5]. Histone modification can alter the condensed chromatin (heterochromatin) structure by influencing histone-DNA and histone-histone contacts [6, 7]. In addition, the chromatin remodeling complex disrupts histone-DNA contacts and induces nucleosome mobilization [8]. The epigenetic marking system "histone code", which modifies the synergistic or antagonistic effects of chromatin-associated proteins on histone-packaged DNA, is a critical mechanism to regulate the transcriptional status of gene expression for coordinated development [9].

Chondrogenesis derived from mesenchymal condensation is a dynamic process in endochondral bone formation. The sequential differentiation and maturation steps of chondrocytes are regulated by transcription factors and growth factors such as the Sry-type high mobility group box (Sox) genes, the runt-related Runx genes, and the transforming growth factor (TGF)- β superfamily [10–12]. Sox9, which encodes a high mobility group DNA-binding domain, has been identified as a master transcription factor in chondrogenesis [13]. Mutations in the *Sox9* gene underlie the congenital dwarfism syndrome, campomelic dysplasia [14]. Mouse chimeras using *Sox9* (-/-) embryonic stem cells shows that *Sox9* (-/-) cells are excluded from cartilage tissues and are unable to express chondrocyte-specific genes such as $\alpha 1(\text{II})$ collagen (*Col2a1*) [15]. In the genital ridge, however, *Col2a1* is not expressed despite abundant *Sox9* expression [16]. In addition, *Sox9* overexpression in chondrocytes produces a phenotype of dwarfism [17]. These findings suggest that additional mechanisms cooperatively regulate the Sox9-dependent chondrogenesis. The TGF- β superfamily is a multifunctional growth factor for many cellular processes such as proliferation, differentiation, and apoptosis [18]. In chondrocyte differentiation, TGF- β stimulation is necessary for MSC-derived primary chondrogenesis [19]. On the other hand, chondrocyte maturation is inhibited by TGF- β [20]. These conflicting effects of TGF- β during chondrogenesis might depend on chromatin structure and/or the epigenetics of each differentiated stage. Several pathways following the activation of

TGF- β receptors such as Smad2, Smad3, and mitogen-activated protein kinase have been identified as key intracellular signals in response to TGF- β treatments [18, 21]. We have previously demonstrated that TGF- β -regulated Smad3 activates the Sox9-dependent transcription on the chromatin structure [22]. Smad3 also associates with other transcription factors, such as the osteogenic inducer Runx2 and the myogenic factor MyoD, and the coactivator p300, which has an intrinsic histone acetyltransferase (HAT) activity [23–25]. From these findings, chondrogenesis is considerably regulated by the cross-talk among transcription factors, growth factor signals, histone modification, and chromatin structure.

Epigenetics is an essential mechanism to control gene expression and fundamental cellular processes such as proliferation and differentiation [26–28]. In this review, we focus on epigenetic regulation during chondrogenic differentiation.

DNA Methylation

DNA methylation is an important epigenetic mechanism for the stable silencing and appropriate maintenance of gene expression [2–4]. DNA methylation in mammals occurs in the cytosine of the CpG nucleotide via DNA methyltransferases. CpG islands, regions with more than 500 bp and a G/C content larger than 55%, are localized in the promoter of about 40% of all mammalian genes and are normally maintained in nonmethylated forms [3, 29]. CpG-rich promoters of chondrogenic-related genes, such as *Sox9*, *Runx2*, *chondromodulin-I*, and *fibroblast growth factor receptor 3*, are hypomethylated during synovium-derived chondrogenesis [30]. In addition, the demethylation status of the *chondromodulin-I* promoter is correlated with *chondromodulin-I* gene expression through the binding of Sp3 as a transcriptional activator [31]. The *Col2a1* gene is also less methylated in chondrocytes than in fibroblasts [32]. CpG methylation-based gene silencing of $\alpha 1(\text{X})$ collagen (*Col10a1*), a hypertrophic marker for differentiated chondrocytes, is consistently established in cartilage tissues and articular chondrocytes. However, the demethylation of the *Col10a1* promoter correlates with *Col10a1* induction during MSC-derived chondrogenesis [33]. These reports suggest that the state of DNA methylation regulates chondrogenic gene expression and cellular

differentiation along with chondrogenesis (Fig. 1). The patterns of genomic methylation are also associated with several human diseases such as ATR-X, Fragile X, and ICF syndromes [34]. DNA methylation is important in determining the gene expression pattern observed in osteoarthritic chondrocytes [35]. On the other hand, CpG methylation does not seem to have a central role in the switch of *aggrecan* promoter activity in articular chondrocytes [36]. Further investigations will be required to understand the relationship between DNA methylation and chondrocyte differentiation.

Histone Modification

Posttranslational histone modification including acetylation, methylation, phosphorylation, ubiquitination, and ADP-ribosylation determines the stability and/or instability of the chromatin structure [7, 9]. External to the histone fold domain, approximately 25% of the core histone mass is contained within the histone tail domain [6]. Histone tails, located at the N-termini of all histones and the C-terminus of H2A, are modified by many enzymes such as HAT, histone deacetylase (HDAC), and histone methyltransferase.




Fig. 1 Epigenetic regulation in the balance between histone acetylation and deacetylation. **A**, Schematic representation of a condensed heterochromatic structure. CpG islands are methylated in the promoter of the inactive (repressed) genes on chromatin. DNA and deacetylated histone form a higher-order chromatin structure via stable histone tails. In heterochromatic regions, the transcription factor (TF) cannot either recognize or associate with its DNA-binding sequence. The repressing molecule and signal (Repressor) favorably associate with TF via the recruitment of corepressor HDAC; **B**, Schematic model of accessible euchromatic environment. TF, the coactivator HAT, and activating molecule (Activator) (e.g. Sox9, p300, and Smad3/4 transcriptional complex) cooperatively induce histone acetylation. The chromatin structure changes from an inactive to accessible form by histone acetylation. In the relaxed euchromatin, other transcriptional complexes cooperatively enhance the transcription of the activated gene. H, histone; Ac, acetylation; Met, methylation.

The N-termini of histone tails interact with DNA and protein in chromatin. Furthermore, histone tails are critical for the self-assembly of condensed chromatin fibers into higher-order structures [6]. The degree of chromatin folding directly influences the activity of DNA in transcription, replication, and recombination [37]. Therefore, histone acetylation of specific lysine residues in the histone tail plays a fundamental role in epigenetic transcriptional regulation (Fig. 1).

Histone Acetylation and HAT Coactivator

Recent biochemical and genetic studies have identified several multisubunit HAT complexes such as coactivator p300 and its paralog CREB-binding protein, the MYST family, and GNAT superfamily members [37, 38]. The multifunctional coactivator p300 has an important role for gene expression and cellular differentiation. p300 acts as a protein scaffold and a bridging factor for the assembly of the transcriptional apparatus. In addition, the HAT activity of p300 has the potential to facilitate transcriptional activity by modulating the chromatin structure [39]. In chondrogenesis, p300 stimulates transcription factor-mediated chromatin disruption. Coactivator p300 directly associates with the master chondrogenic factor Sox9, and activates Sox9-dependent transcription [40]. We have previously reported that Sox9-dependent transactivation is induced by p300-mediated histone acetylation of chromatin [41]. *In vitro* transcription and S1 nuclease assays have revealed that p300 potentiates Sox9-dependent transcription on a chromatinized DNA template and is associated with hyperacetylated histones [41]. In addition, histone hyperacetylation using the HDAC inhibitor trichostatin A (TSA) enhances Sox9-regulated cartilage matrix gene expressions (*COL2A1* and *aggrecan*) in human chondrocytes [41]. HDAC inhibitors, including TSA and FK228, have the synergistic potential to induce *Sox9* expression via enhanced recruitment of nuclear factor Y (NF-Y) to the proximal promoter of *Sox9* [42]. p300 also acts as a transcriptional coactivator of cartilage homeoprotein-1 (*Cart1*), which is involved in skeletal development, through direct interaction with *Cart1*. Deletion and mutagenesis analyses have identified that the 131st lysine of *Cart1* is acetylated by p300-HAT, and that *Cart1* acetylation is critical in the association with p300 as well as p300-dependent

transactivation [43]. Gene activation of the *cartilage oligomeric matrix protein (COMP)*, encoding a noncollagenous matrix protein expressed predominantly in cartilage, is cooperatively regulated by Sox9, Sox5, Sox6, and p300 [44]. The *COMP* promoter contains a positive and negative regulatory element. Sox9 directly binds to the positive regulatory element and activates *COMP* expression by associating with p300 [44]. On the other hand, the leukemia/lymphoma-related factor transcriptional repressor inhibits *COMP* gene expression by recruiting HDAC1 as a negative regulatory element of the *COMP* promoter [45]. Tat-interactive protein-60 (Tip60) is a member of the MYST family involved in a wide range of regulatory functions in various organisms [38]. Coactivator Tip60, which mainly acetylates H4, increases Sox9/Sox5-dependent *Col2a1* transcription by associating with Sox9 on chromatin [46]. The basic helix-loop-helix transcription factor, Scleraxis, and its partner, E47, cooperatively stimulate Sox9-dependent transcription through the formation of a transcriptional complex with p300 [47]. These findings suggest that coactivator-induced histone acetylation triggers the transcriptional activation of chondrogenic genes and has a fundamental role in epigenetic regulation during chondrogenesis.

Histone Deacetylation and HDAC Corepressor

Acetylation of lysine residues in histone tails neutralizes their positive charge, thereby relaxing the chromatin (euchromatin) structure. This interferes with the generation of higher-order chromatin structures, and increases the accessibility of transcription factors to their target genes [48]. Histone deacetylation induced by HDACs has a crucial role in chromatin compaction and transcriptional repression. Therefore, the balance between histone acetylation and deacetylation serves as a key regulatory mechanism for gene expression, developmental processes, and disease states [49]. HDACs lack intrinsic DNA-binding activity and are recruited to target genes via their direct association with transcriptional activators and repressors, as well as their incorporation into multiprotein transcriptional complexes [48]. Mammalian genomes encode 11 HDAC proteins with a highly conserved deacetylase domain. Recent analyses of *HDAC* knockout mice have revealed specific functions

of individual HDACs in development and disease [49]. In chondrogenesis, HDAC4 has a central role in skeletal development [50]. HDAC4, which is expressed in prehypertrophic chondrocytes, regulates chondrocyte hypertrophy and endochondral bone formation by interacting with and inhibiting the activity of Runx2 [50]. *HDAC4*-null mice display premature ossification of developing bone due to early induction of chondrocyte hypertrophy, and die during the first week of life owing to ectopic ossification, which prevents the expansion of the rib cage and leads to an inability to breathe [50]. Adenoviral *HDAC4* overexpression promotes synovial stem cell-derived chondrogenesis but inhibits its hypertrophic differentiation [51]. In cultured chondrocytes, total HDAC activity and *Col2a1* expression decrease along with the dedifferentiation in passaged chondrocytes, but recover during the redifferentiation in pellet-cultured chondrocytes [52]. This phenomenon seems to be caused by HDAC-mediated transcriptional suppression of *Wnt-5a*, which inhibits *Col2a1* expression [52]. On the other hand, transcription factor Snail inhibits the expression of the *Col2a1* gene by associating with HDAC1 and HDAC2 [53]. These reports suggest that histone deacetylation is complicatedly modified by transcription factor-related HDACs. The balance between histone acetylation and deacetylation is tightly regulated by many transcriptional complexes during chondrogenic differentiation and maturation (Fig. 1).

Growth Factors and Epigenetics

Growth factors, cytokines, and nonproteinaceous chemical compounds including dexamethasone, vitamin D₃, prostaglandin E₂, and ascorbic acid influence gene expression and cellular differentiation during chondrogenesis [54]. Intracellular signaling activated by the ligand-receptor complex also plays an important role in epigenetic regulation by modulating the association between transcription factors and coactivators/corepressors. The TGF- β superfamily and its signal mediators are well-documented in the field of chondrocyte differentiation, maturation, and degeneration [55]. TGF- β -regulated Smad3, but not Smad2, promotes MSC-derived primary chondrogenesis through the activation of Sox9 via p300 recruitment [56]. Smad3 stabilizes the association between Sox9 and coactivator p300 by forming a transcrip-

tional apparatus with Sox9/p300 [56]. Phosphorylated Smad3/4, Sox9, and p300 cooperatively activate the Sox9-dependent transcription on a chromatinized DNA template [22]. Bone morphogenetic protein (BMP)-2, a member of the TGF- β superfamily, stimulates *Sox9* expression by increasing the association between NF-Y-p300 complex and *Sox9* promoter. BMP-2 also induces histone hyperacetylation and methylation at the *Sox9* gene on chromatin [57]. Chondrocyte terminal differentiation is stimulated by the activation of BMP-regulated Smad1/5/8 and inhibited by the TGF- β -regulated Smad2/3 pathway [55]. Although the interaction between Smad1 and Runx2 is essential for Runx2-dependent transcription, the Runx2-Smad3 complex inhibits the function of Runx2 [58]. The BMP-activated Smad1/4 complex associates with Nkx3.2, expressed in the sclerotome and developing cartilage, by facilitating the recruitment of corepressor HDAC1 [59]. The studies cited demonstrate that the interaction between the transcription factor and TGF- β /BMP-dependent Smad can result in either transcriptional activation or repression (Fig. 1). The growth factor-regulated signal may have the potential to activate (or repress) target gene expression by stabilizing the association between the transcription factor and the coactivator (or corepressor).

Epigenetics in Chondrogenic Differentiation

Epigenetics plays an essential role in determining the course of cellular differentiation and gene expression modulation without disrupting genetic information. DNA methylation correlates with gene silencing during chondrogenesis. Histone acetylation and deacetylation, which mainly modulate a relaxed and/or condensed chromatin structure, are precisely regulated by transcription factor-related complex formation with coactivator HATs and with corepressor HDACs, respectively. The “epigenetic code” maintains subconscious developmental memories in chondrogenic differentiation [60, 61].

Acknowledgments. We thank Dr. Hiroshi Asahara for his kind advice in preparing this review. We are also grateful to our colleagues at the Department of Orthopaedic Surgery for their continuing support.

References

1. Kragl M, Knapp D, Nacu E, Khattak S, Maden M, Epperlein HH and Tanaka EM: Cells keep a memory of their tissue origin during axolotl limb regeneration. *Nature* (2009) 460: 60–65.
2. Jones PA and Takai D: The role of DNA methylation in mammalian epigenetics. *Science* (2001) 293: 1068–1070.
3. Quina AS, Buschbeck M and Di Croce L: Chromatin structure and epigenetics. *Biochem Pharmacol* (2006) 72: 1563–1569.
4. Reik W, Dean W and Walter J: Epigenetic reprogramming in mammalian development. *Science* (2001) 293: 1089–1093.
5. Okano M, Bell DW, Haber DA and Li E: DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* (1999) 99: 247–257.
6. Wolffe AP and Hayes JJ: Chromatin disruption and modification. *Nucleic Acids Res* (1999) 27: 711–720.
7. Strahl BD and Allis CD: The language of covalent histone modifications. *Nature* (2000) 403: 41–45.
8. Ko M, Sohn DH, Chung H and Seong RH: Chromatin remodeling, development and disease. *Mutat Res* (2008) 647: 59–67.
9. Jenuwein T and Allis CD: Translating the histone code. *Science* (2001) 293: 1074–1080.
10. Akiyama H, Chaboissier MC, Martin JF, Schedl A and de Crombrughe B: The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. *Genes Dev* (2002) 16: 2813–2828.
11. Stricker S, Fundele R, Vortkamp A and Mundlos S: Role of Runx genes in chondrocyte differentiation. *Dev Biol* (2002) 245: 95–108.
12. Shi Y and Massagué J: Mechanisms of TGF- β signaling from cell membrane to the nucleus. *Cell* (2003) 113: 685–700.
13. Kamachi Y, Uchikawa M and Kondoh H: Pairing SOX off: with partners in the regulation of embryonic development. *Trends Genet* (2000) 16: 182–187.
14. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, Wolf U, Tommerup N, Schempp W and Scherer G: Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. *Cell* (1994) 79: 1111–1120.
15. Bi W, Deng JM, Zhang Z, Behringer RR and de Crombrughe B: Sox9 is required for cartilage formation. *Nat Genet* (1999) 22: 85–89.
16. Zhao Q, Eberspaecher H, Lefebvre V and de Crombrughe B: Parallel expression of Sox9 and Col2a1 in cells undergoing chondrogenesis. *Dev Dyn* (1997) 209: 377–386.
17. Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, Zhang R, Zhang Z, Deng JM, Taketo MM, Nakamura T, Behringer RR, McCreagh PD and de Crombrughe B: Interactions between Sox9 and β -catenin control chondrocyte differentiation. *Genes Dev* (2004) 18: 1072–1087.
18. Liu F: Receptor-regulated Smads in TGF- β signaling. *Front Biosci* (2003) 8: s1280–1303.
19. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. *Science* (1999) 284: 143–147.
20. Ferguson CM, Schwarz EM, Reynolds PR, Puzas JE, Rosier RN and O'Keefe RJ: Smad2 and 3 mediate transforming growth factor- β 1-induced inhibition of chondrocyte maturation. *Endocrinology* (2000) 141: 4728–4735.
21. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K and Nishida E: Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor- β -induced gene expression. *J Biol Chem* (1999) 274: 27161–27167.
22. Furumatsu T, Ozaki T and Asahara H: Smad3 activates the Sox9-dependent transcription on chromatin. *Int J Biochem Cell Biol* (2009) 41: 1198–1204.
23. Alliston T, Choy L, Ducy P, Karsenty G and Derynck R: TGF- β -induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. *EMBO J* (2001) 20: 2254–2272.
24. Liu D, Black BL and Derynck R: TGF- β inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. *Genes Dev* (2001) 15: 2950–2966.
25. Nishihara A, Hanai JI, Okamoto N, Yanagisawa J, Kato S, Miyazono K and Kawabata M: Role of p300, a transcriptional coactivator, in signalling of TGF- β . *Genes Cells* (1998) 3: 613–623.
26. Li E: Chromatin modification and epigenetic reprogramming in mammalian development. *Nat Rev Genet* (2002) 3: 662–673.
27. Jaenisch R and Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* (2003) 33: Suppl. 245–254.
28. Felsenfeld G and Groudine M: Controlling the double helix. *Nature* (2003) 421: 448–453.
29. Bird AP and Wolffe AP: Methylation-induced repression—belts, braces, and chromatin. *Cell* (1999) 99: 451–454.
30. Ezura Y, Sekiya I, Koga H, Muneta T and Noda M: Methylation status of CpG islands in the promoter regions of signature genes during chondrogenesis of human synovium-derived mesenchymal stem cells. *Arthritis Rheum* (2009) 60: 1416–1426.
31. Aoyama T, Okamoto T, Nagayama S, Nishijo K, Ishibe T, Yasura K, Nakayama T, Nakamura T and Toguchida J: Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3. *J Biol Chem* (2004) 279: 28789–28797.
32. Fernández MP, Young MF and Sobel ME: Methylation of type II and type I collagen genes in differentiated and dedifferentiated chondrocytes. *J Biol Chem* (1985) 260: 2374–2378.
33. Zimmermann P, Boeuf S, Dickhut A, Boehmer S, Olek S and Richter W: Correlation of COL10A1 induction during chondrogenesis of mesenchymal stem cells with demethylation of two CpG sites in the COL10A1 promoter. *Arthritis Rheum* (2008) 58: 2743–2753.
34. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. *Nature* (2004) 429: 457–463.
35. Roach HI and Aigner T: DNA methylation in osteoarthritic chondrocytes: a new molecular target. *Osteoarthritis Cartilage* (2007) 15: 128–137.
36. Pöschl E, Fidler A, Schmidt B, Kallipolitou A, Schmid E and Aigner T: DNA methylation is not likely to be responsible for aggrecan down regulation in aged or osteoarthritic cartilage. *Ann Rheum Dis* (2005) 64: 477–480.
37. Roth SY, Denu JM and Allis CD: Histone acetyltransferases. *Annu Rev Biochem* (2001) 70: 81–120.
38. Sterner DE and Berger SL: Acetylation of histones and transcription-related factors. *Microbiol Mol Biol Rev* (2000) 64: 435–459.
39. Chan HM and La Thangue NB: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. *J Cell Sci* (2001) 114: 2363–2373.

40. Tsuda M, Takahashi S, Takahashi Y and Asahara H: Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9. *J Biol Chem* (2003) 278: 27224–27229.
41. Furumatsu T, Tsuda M, Yoshida K, Taniguchi N, Ito T, Hashimoto M, Ito T and Asahara H: Sox9 and p300 cooperatively regulate chromatin-mediated transcription. *J Biol Chem* (2005) 280: 35203–35208.
42. Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA and Hanley NA: Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. *J Biol Chem* (2008) 283: 14063–14071.
43. Iioka T, Furukawa K, Yamaguchi A, Shindo H, Yamashita S and Tsukazaki T: P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain. *J Bone Miner Res* (2003) 18: 1419–1429.
44. Liu CJ, Zhang Y, Xu K, Parsons D, Alfonso D and Di Cesare PE: Transcriptional activation of cartilage oligomeric matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 coactivators. *Front Biosci* (2007) 12: 3899–3910.
45. Liu CJ, Prazak L, Fajardo M, Yu S, Tyagi N and Di Cesare PE: Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. *J Biol Chem* (2004) 279: 47081–47091.
46. Hattori T, Coustry F, Stephens S, Eberspaecher H, Takigawa M, Yasuda H and de Crombrughe B. Transcriptional regulation of chondrogenesis by coactivator Tip60 via chromatin association with Sox9 and Sox5. *Nucleic Acids Res* (2008) 36: 3011–3024.
47. Furumatsu T, Shukunami C, Amemiya-Kudo M, Shimano H and Ozaki T: Scleraxis and E47 cooperatively regulate the Sox9-dependent transcription. *Int J Biochem Cell Biol* (2010) 42: 148–156.
48. Shahbazian MD and Grunstein M: Functions of site-specific histone acetylation and deacetylation. *Annu Rev Biochem* (2007) 76: 75–100.
49. Haberland M, Montgomery RL and Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. *Nat Rev Genet* (2009) 10: 32–42.
50. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G and Olson EN: Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. *Cell* (2004) 119: 555–566.
51. Pei M, Chen D, Li J and Wei L: Histone deacetylase 4 promotes TGF- β 1-induced synovium-derived stem cell chondrogenesis but inhibits chondrogenically differentiated stem cell hypertrophy. *Differentiation* (2009) 78: 260–268.
52. Huh YH, Ryu JH and Chun JS: Regulation of type II collagen expression by histone deacetylase in articular chondrocytes. *J Biol Chem* (2007) 282: 17123–17131.
53. Hong S, Derfoul A, Pereira-Mouries L and Hall DJ: A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. *FASEB J* (2009) 23: 3539–3552.
54. Heng BC, Cao T and Lee EH: Directing stem cell differentiation into the chondrogenic lineage in vitro. *Stem Cells* (2004) 22: 1152–1167.
55. van der Kraan PM, Blaney Davidson EN, Blom A and van den Berg WB: TGF-beta signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. *Osteoarthritis Cartilage* (2009) 17: 1539–1545.
56. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y and Asahara H: Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. *J Biol Chem* (2005) 280: 8343–8350.
57. Pan Q, Wu Y, Lin T, Yao H, Yang Z, Gao G, Song E and Shen H: Bone morphogenetic protein-2 induces chromatin remodeling and modification at the proximal promoter of Sox9 gene. *Biochem Biophys Res Commun* (2009) 379: 356–361.
58. Kang JS, Alliston T, Delston R and Derynck R: Repression of Runx2 function by TGF- β through recruitment of class II histone deacetylases by Smad3. *EMBO J* (2005) 24: 2543–2555.
59. Kim DW and Lassar AB: Smad-dependent recruitment of a histone deacetylase/Sin3A complex modulates the bone morphogenetic protein-dependent transcriptional repressor activity of Nkx3.2. *Mol Cell Biol* (2003) 23: 8704–8717.
60. Furumatsu T: Sox9-dependent transcription in chondrogenesis. *J Joint Surg* (2008) 27: 146–147 (in Japanese).
61. Furumatsu T: Sox9-related epigenetic regulation. *Orthop Surg Trauma* (2009) 52: 1040–1041 (in Japanese).